SELLAS Life Sciences Group Inc. (SLS)
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
SLS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.28B
- EPS (TTM)
- -$0.21
- Dividend yield
- None
- 52-week range
- 1.39 – 15.88
- Day range
- 11.15 – 11.54
- Volume / Avg
- 3.13M / 6.75M
- Beta
- —
- Shares outstanding
- 201.95M
- Next earnings
- Nov 11, 2026
52-week range
SLS stock today
SELLAS Life Sciences Group (SLS) closed at $11.31 on Oct 7, down 0.26% (-$0.03), versus the S&P 500's 0.22% decline. Trading was light, with 3.13M shares changing hands, about 46% of the average daily volume. At this level, SLS sits in the middle of its 52-week range of $1.39 to $15.88: 28.8% below the high, set on Jun 30, 2026 and 713.7% above the low.
SLS is up 200.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 495.3%. SELLAS Life Sciences Group has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful. SELLAS Life Sciences Group's next earnings report is expected on Nov 11, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About SELLAS Life Sciences Group
Company profileSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Angelos M. Stergiou M.D., ScD h.c.
- Headquarters
- New York, NY
- Employees
- 13
- Website
- sellaslifesciences.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$32.50+187.36%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 11, 2026
SELLAS Life Sciences Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs SLS |
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs SLS |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs SLS |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs SLS |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs SLS |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs SLS |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs SLS |
| LQDALiquidia Corporation | 26.68 | +2.97% | $2.39B | vs SLS |
Indexes, lists and sector
SELLAS Life Sciences Group stock FAQ
What is SELLAS Life Sciences Group's stock price today?
SLS last traded at $11.31 as of Oct 7, 4:00 PM EDT, down 0.26% on the day. Prices are delayed at least 15 minutes.
Does SELLAS Life Sciences Group pay a dividend?
No. SELLAS Life Sciences Group does not currently pay a regular cash dividend.
When is SELLAS Life Sciences Group's next earnings date?
SELLAS Life Sciences Group is expected to report earnings on Wednesday, November 11, 2026.
Who is SELLAS Life Sciences Group's CEO?
Dr. Angelos M. Stergiou M.D., ScD h.c. is the chief executive officer of SELLAS Life Sciences Group Inc., which has about 13 employees.
Has SLS ever split its stock?
Yes. The most recent SLS stock split was a 1-for-50 split on Nov 8, 2019, one of 3 splits on record.
What is the SLS 52-week high?
The 52-week high for SLS is $15.88 and the 52-week low is $1.39. The stock is currently 28.8% below its high.